Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 661

1.

Erratum to the importance of incorporating smoking cessation into lung cancer screening.

[No authors listed]

Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S303. doi: 10.21037/tlcr.2018.09.02.

2.

Erratum: The association between human papillomavirus presence and epidermal growth factor receptor mutations in Asian patients with non-small cell lung cancer.

Liang H, Pan Z, Cai X, Wang W, Guo C, He J, Chen Y, Liu Z, Wang B, He J, Liang W.

Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S302. doi: 10.21037/tlcr.2018.07.14.

3.

Multidisciplinary quality improvement initiative to standardize reporting of lung cancer screening.

Cubillos L, Brenner AT, Birchard K, Henderson LM, Molina PL, Pignone M, Ratner S, Rivera MP, Jones L, Reuland DS.

Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S297-S301. doi: 10.21037/tlcr.2018.09.08.

4.

Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

Metro G, Di Maio M.

Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S294-S296. doi: 10.21037/tlcr.2018.07.12. No abstract available.

5.

Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

Metro G, Di Maio M.

Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S290-S293. doi: 10.21037/tlcr.2018.07.11. No abstract available.

6.

PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

Addeo A, Banna GL.

Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S287-S289. doi: 10.21037/tlcr.2018.07.09. No abstract available.

7.

PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

Addeo A, Banna GL.

Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S283-S286. doi: 10.21037/tlcr.2018.07.10. No abstract available.

8.

Dose-escalation of locally advanced non-small cell lung cancer with proton beam therapy.

Verma V, Chang JY.

Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S280-S282. doi: 10.21037/tlcr.2018.04.08. No abstract available.

9.

Programmed cell death ligand-1 (PD-L1) as a biomarker for non-small cell lung cancer (NSCLC) treatment-are we barking up the wrong tree?

Dempke WCM, Fenchel K, Dale SP.

Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S275-S279. doi: 10.21037/tlcr.2018.04.18.

10.

Tobacco cessation in lung cancer screening-do we have the evidence?

Stone E, Marshall H.

Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S270-S274. doi: 10.21037/tlcr.2018.09.09. No abstract available.

11.

Identifying therapeutic vulnerabilities in lung cancer: application of a chemistry-first approach.

Pine SR, Ryan BM.

Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S265-S269. doi: 10.21037/tlcr.2018.09.10. No abstract available.

12.

Finding paths with the greatest chance of success: enabling and focusing lung cancer screening and cessation in resource-constrained areas.

Jenkins WD, Gilbert D, Chen LS, Carnahan LR.

Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S261-S264. doi: 10.21037/tlcr.2018.09.11. No abstract available.

13.

Thymic tumors with parathymic syndromes: good or bad?

Dell'Amore A, Campisi A.

Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S258-S260. doi: 10.21037/tlcr.2018.09.07. No abstract available.

14.

Hunting for transcription factors: STAT3 decoy in non-small cell lung cancer.

Carmicheal J, Kaur S, Batra SK, Ganti AK.

Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S254-S257. doi: 10.21037/tlcr.2018.09.06. No abstract available.

15.

Subtype variation and actionability of telomere length abnormality in lung cancer.

Goh F, Yang IA, Bowman RV, Fong KM.

Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S251-S253. doi: 10.21037/tlcr.2018.09.03. No abstract available.

16.

Studying the immune landscape in lung cancer models: choosing the right experimental tools.

Weeden CE, Ah-Cann C, Asselin-Labat ML.

Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S248-S250. doi: 10.21037/tlcr.2018.09.05. No abstract available.

17.

Targeting IL22: a potential therapeutic approach for Kras mutant lung cancer?

Weinberg FD, Ramnath N.

Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S243-S247. doi: 10.21037/tlcr.2018.09.04. No abstract available.

18.

LACES and bootstraps: the hunt for prognostic and predictive markers for adjuvant therapy in NSCLC.

Lee RC, Thapa B, John T.

Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S239-S242. doi: 10.21037/tlcr.2018.09.01. No abstract available.

19.

The impact of patients' preferences on the decision of low-dose computed tomography lung cancer screening.

Wu FZ, Kuo PL, Wu CC, Wu MT.

Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S236-S238. doi: 10.21037/tlcr.2018.08.17. No abstract available.

20.

Intraoperative molecular imaging-a bright navigator for thoracic surgeons in the era of limited resection.

Suda K.

Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S232-S235. doi: 10.21037/tlcr.2018.08.13. No abstract available.

Supplemental Content

Loading ...
Support Center